Whether we partied and danced at Limbo, Jules or any of a myriad of clubs and pubs then or now, Adelaide has had a varied after-dark experience. With CityMag staffers spanning generations, it became clear our nightlife experiences have changed over time.
Foghorn Therapeutics Announces Chief Medical Officer Succession streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Infinity Pharmaceuticals, Inc. , a clinical-stage biotechnology company developing eganelisib, a potential first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic, today announced.
Infinity Pharmaceuticals Announces Value Preservation and Maximization Plan streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Share:
CAMBRIDGE, Mass., Feb. 22, 2021 (GLOBE NEWSWIRE) Foghorn Therapeutics Inc. (NASDAQ:FHTX), a company pioneering the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system, today announced that Sam Agresta, M.D., M.P.H, Chief Medical officer is scheduled to participate in a Leukemias panel discussion at the Cowen 41
st Annual Healthcare Conference at 11:40 a.m. ET on March 3, 2021.
About Foghorn Therapeutics
Foghorn
® Therapeutics is discovering and developing a novel class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Through its proprietary scalable Gene Traffic Control
® platform, Foghorn is systematically studying, identifying and validating potential drug targets within the chromatin regulatory system. The company is developing multiple product candidates in oncology.